Chronic kidney disease (CKD)

View All

xphozah-for-chronic-kidney-disease-treatment
Ardelyx Overcomes Hurdles to Secure FDA Approval for Xphozah in Chronic Kidney Disease Treatment

Ardelyx has struck gold on its third attempt with Xphozah (tenapanor), the chronic kidney disease medication. Following two prior rejections, the FDA has granted its long-awaited approval. Xphozah, an innovative phosphate absorption inhibitor, is now officially sanctioned for the management of serum phosphate level...

Find More

chronic-kidney-disease-ckd-treatment
Evolving Therapeutics in Chronic Kidney Disease (CKD) Treatment Market

Chronic kidney disease burden and diagnostic barriers Chronic kidney disease (CKD) is a progressive and irreversible ailment characterized by gradual loss of kidney function. It is clinically defined by a glomerular filtration rate of less than 60mL/min/1.73m2 or albuminuria of at least 30mg per 24 hours, or any...

Find More

Pharma News Updates Merck, Regeneron, Provention, Ardelyx, AbbVie
FDA Approves Teplizumab to Delay the Onset of Type 1 Diabetes; FDA Backs Ardelyx’s CKD Therapy Xphozah; Merck to Acquire Imago BioSciences; Accelerated Approval to ImmunoGen’s ELAHERE; Regeneron and CytomX Announces Research Collaboration; FDA Grants Priority Review to Epcoritamab R/R LBCL

Merck to Acquire Imago BioSciences, Inc. for USD 1.35 Billion While its rumored acquisition of Seagen has yet to materialize, Merck & Co has continued to bolster its pipeline with smaller transactions, the most recent of which was a USD 1.35 billion agreement to acquire Imago BioSciences and its bomedemstat ...

Find More

Pharma News for Amgen BioNTech and Gilead
Amgen Announced the Result of its CodeBreak-200 Trial; FDA Clears Bristol-Myers Squibb’s Deucravacitinib; BioNTech’s Amplified CAR-T Therapy; TIL Therapy Improves on Yervoy in Melanoma; GSK’s Daprodustat will have to face FDA Advisory Committee; Breakthrough Therapy Status to Pfizer’s Group B Strep Vaccine; EU Approves Gilead’ Tecartus; Gilead’ Trodelvy Results in TROPiCs-02 Trial

Amgen Reveals the Top-line Result of its CodeBreak-200 trial of Lumakras in Lung Cancer The top-line result of Amgen's CodeBreak-200 trial of Lumakras in lung cancer was presented in abstract form at ESMO two weeks ago, showing a 34% improvement in progression-free survival (PFS) compared to chemotherapy. The fu...

Find More

pharma-happenings-for-jnj-bayer-novo-prothena
Bayer’s CKD Drug; Enochian’s RNA Hijack for HBV; Novo Nordisk’s to get Prothena’s ATTR Amyloidosis Business; J&J’s COVID-19 Vaccine Struggle

Bayer Scores FDA-Approval for its CKD Drug Finerenone Following a priority review, the USFDA finally gave its thumbs-up to Bayer AG’s Kerendia (finerenone) for chronic kidney disease (CKD) associated with type 2 diabetes (T2D) based on the results from the Phase III FIDELIO-DKD study. Finerenone is the first ...

Find More

Pfizer/BioNTech COVID-19 Vaccine; Biogen/Capsigen Deal
Abingworth & Alebund’s Finacial Closing; Pfizer/BioNTech COVID-19 Vaccine Expanded Use; Biogen and Capsigen Deal

Abingworth Achieves Financial Close, Raises USD 582 Million Abingworth, a London-based venture capital firm, has announced the closing of its new Clinical Co-Development Fund 2 (ACCD 2) worth USD 582 million, however, the fund was aiming to gather USD $350 million.  Not long ago, the company also closed ...

Find More

Evotec, Chinook's CKD Therapy; Junshi, AZ with Toripalimab in China
Evotec, Chinook Teams Up for CKD Therapy; HitGen & UPPTHERA in Drug Delivery Research; Artiva’s $120 M Coup of NK Cell Therapy; Junshi & AZ with Toripalimab in China

Evotec, Chinook Therapeutics to Advance Chronic Kidney Diseases Therapy Market Evotec and Chinook Therapeutics have collaborated to develop and discover precision medicine therapies for patients with chronic kidney diseases (CKD). The duo plans to jointly identify, characterize and validate novel mechanisms and ...

Find More

world kidney day
World Kidney Day

World Kidney Day World Kidney Day is a global awareness campaign for raising awareness of the importance of our kidneys. 850 MILLION PEOPLE WORLDWIDE are now estimated to have kidney diseases from various causes. Chronic kidney disease (CKD) causes at least 2.4 million deaths per year and is now the 6th fastest ...

Find More